Warner Chilcott Buyout Values Women’s Health Rx Firm At $3 Bil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Buyout by DLJ and J.P. Morgan investment groups will complete transformation of U.K. company into U.S.-focused specialty women’s health firm. Investor group plans to retain current Warner Chilcott management following sale.
You may also be interested in...
Warner Chilcott Takes Itself Off The Market; Special Dividend Disappoints
Warner Chilcott has ended all discussions with parties potentially interested in buying the company and tried to satisfy investors with a special dividend as a consolation prize.
FTC, States Sue Barr, Warner Chilcott Over Ovcon-35 Deal
Lawsuit claims companies' agreement regarding generic Ovcon-35 was anti-competitive.
FTC, States Sue Barr, Warner Chilcott Over Ovcon-35 Deal
Lawsuit claims companies' agreement regarding generic Ovcon-35 was anti-competitive.